APA (7th ed.) Citation

C, C., P, R., MA, R., G, M., A, C., F, C., . . . R, R. (2020). The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials, 21(1), 498. https://doi.org/10.1186/s13063-020-04421-z

Chicago Style (17th ed.) Citation

C, Chaccour, et al. "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in Low Risk, Non-severe COVID-19 Patients in the First 48 Hours After Symptoms Onset: A Structured Summary of a Study Protocol for a Randomized Control Pilot Trial." Trials 21, no. 1 (2020): 498. https://doi.org/10.1186/s13063-020-04421-z.

MLA (9th ed.) Citation

C, Chaccour, et al. "The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in Low Risk, Non-severe COVID-19 Patients in the First 48 Hours After Symptoms Onset: A Structured Summary of a Study Protocol for a Randomized Control Pilot Trial." Trials, vol. 21, no. 1, 2020, p. 498, https://doi.org/10.1186/s13063-020-04421-z.